VTGN Valuation

Vistagen Therapeutics Inc

Add to Watchlist

Advanced Chart

3.080

+0.37(13.653%)1D

Overview
Forecast
Valuation
Earnings

VTGN Relative Valuation

VTGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VTGN is overvalued; if below, it's undervalued.

Historical Valuation

Vistagen Therapeutics Inc (VTGN) is now in the Fair zone, suggesting that its current forward PS ratio of 178.67 is considered Fairly compared with the five-year average of -3.72. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.64 to 6.13 according to relative valuation methord.

Relative Value

Fair Zone

1.64-6.13

Current Price：3.08

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.27

P/B

Median3y

1.46

Median5y

2.79

-53.52

FCF Yield

Median3y

-97.23

Median5y

-62.86

Competitors Valuation Multiple

The average P/S ratio for VTGN's competitors is 30.87, providing a benchmark for relative valuation. Vistagen Therapeutics Inc Corp (VTGN) exhibits a P/S ratio of 178.67, which is 478.84% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VTGN.O

Vistagen Therapeutics Inc

178.67

Average P/S: 30.87

-100.00%